Regulus slashes IPO price; Durata Therapeutics to move R&D to Connecticut; Black mamba venom contains powerful pain reliever;

Conversations on Twitter :

 @FierceBiotech: Merger deal gives generic drugmaker control of troubled BioSante. More | Follow @FierceBiotech

 @JohnCFierce: 2012 Fierce 15 winner Aragon raises $50M for 509 program. That's $88M this year. More | Follow @JohnCFierce

 @RyanMFierce: BioSante goes the way of the M&A. More | Follow @RyanMFierce

> Regulus has slashed its IPO price from a range of $10 to $12 a share down to only $4. Story

> Durata Therapeutics has gained some incentives from Connecticut as it preps a move to the state. Durata will move R&D and other operations from New Jersey to Connecticut, with promises to eventually create 80 new jobs. Release

> Antaras Pharma plans to raise $47 million through the sale of shares. The company is developing new delivery systems for therapies. Report

> Ember Therapeutics, a 2012 Fierce 15 company, says it has gained the exclusive option rights to intellectual property for three key small molecule targets: retinaldehyde dehydrogenase 1 (Aldh1a1), thioesterase superfamily member 1 (Them1), and TRPV4. Release

> Reuters has profiled Belgium's growing biotech industry. Story

Pharma News

@FiercePharma: J&J's trying to block testimony from ex-FDA chief David Kessler, who calls its Risperdal marketing "deeply troubling." More | Follow @FiercePharma

> Teva yanks Wellbutrin copy after FDA says it's not equivalent to brand. News

> India nixes Pfizer's patent on cancer-fighter Sutent. Story

> Mylan sues FDA to revoke Ranbaxy's Diovan exclusivity. Report

Medical Device News

 @FierceMedDev: Alere has reached a deal with the FDA on Dx production, looking to move past May's recall of 800K test kits. More | Follow @FierceMedDev

 @MarkHFierce: Sony may be boosting its involvement in med tech, but investors are worried the company is going down a sinkhole. More | Follow @MarkHFierce

 @DamianFierce: Medtronic's next-gen renal denervation device takes a page from the St. Jude tech Medtronic earlier dismissed. More | Follow @DamianFierce

> Life Technologies, CollabRx, forge molecular Dx data deal. Article

> Judge: BD violated Hologic's patents. News

> Tyrx gains Canadian regualtory nod for antibacterial envelope. Story

Pharma Manufacturing News

> Square Pharmaceuticals opening 2 plants in Bangladesh. News

> Merck whacking 20% of jobs at Ireland API plant. Story

> New Janssen distribution hub consolidates European supply chain. Article

Vaccines News

> Novartis vaccines unit's future hangs on Bexsero approval. Article

> NIH awards $1.38M to professor for HIV vaccine research. Item

> Merck's Gardasil earns high safety marks. Story

> Flu vaccine manufacturers face steep odds. News

And Finally… French scientists say they have discovered that the venom from the lethal black mamba snake contains a pain reliever that is as strong as morphine with none of the side effects. Story

 

Suggested Articles

Joe Jimenez has (another) new gig. The ex-Novartis boss joined the board of Century Therapeutics, a startup working on off-the-shelf cell therapies.

As Pfizer posts its full-year financials today, as usual it’s also sneaked in several dropped projects from its pipeline.

The short seller thinks Principia’s approach to the treatment of autoimmune diseases is “misguided” and likely to lead to clinical failures.